Description
Generic Version of Deferasirox Dispersible Available in India?
Deferasirox Dispersible is the generic name of the medication and is its international nonproprietary name. It is marketed under the brand name Asunra among others.
Deferasirox is used to remove excess iron from the body in patients who have had too many blood transfusions and in patients with non-transfusion dependent thalassemia syndromes. Deferasirox is an iron chelator (binder). It combines with iron in the blood.
Will this product be accessible across all regions of India?
The product – Asunra (Deferasirox Dispersible) Tablets will be available across India on request. Deferasirox Dispersible is available in all the major cities in India – Delhi, Chandigarh, Jodhpur, Patna, Kolkata, Lucknow, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune.
We’re here to help
Any patient, doctor, hospital, pharmacy, B2C and healthcare consultant can reach Aark Pharmaceuticals, a CFA, Distributors & Retailers in Delhi India. Request to call us at+91 9999156233, You can also make an inquiry by emailing us at sales@aarkpharma.co.in, sales@aarkpharma.com, WhatsApp: +91 9999156233.
List of available brand-name drugs for Deferasirox Dispersible Tablets
Brand Name for Deferasirox Dispersible: Asunra
NEWS / Updates
- Ali Taher, Amal El-Beshlawy, Mohsen S Elalfy, Kusai Al Zir, Shahina Daar, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, and Abdullah Al Jefri. Uses of Deferasirox. National Institute of Health. NIH National Centre for Biotechnology Information. Pubmed.gov. June 2009. [Accessed on 20th June 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730551/
- Novartis Pharmaceuticals UK Ltd. Electronic Medicines Compendium (EMC). [Revised in March 2021] [Accessed on 20th June 2022] https://www.medicines.org.uk/emc/files/pil.4329.pdf
- Mylan Pharmaceuticals Limited. European Medical Agency (EMA). [Revised in September 2019] [Accessed on 20th June 2022] https://www.ema.europa.eu/en/documents/product-information/deferasirox-mylan-epar-product-information_en.pdf
- Novartis Pharma Stein AG. U.S. Food & Drug Administration. [Revised in October 2013] [Accessed on 20th June 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021882s019lbl.pdf
- Deferasirox. Accord Healthcare Polska Sp.z.o.o. [Revised in December 2021 [Accessed on 20th June 2022] https://cdn.accord-healthcare.com/ie/public/pil/eu_deferasirox_accord_ema-combined-h-5156-en-ib04_version4_-_pil_0.pdf
- Zydus Pharmaceuticals (USA) Inc. Deferasirox. [Revised in August 2021 [Accessed on 20th June 2022] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4af5bc9e-3e09-4dfd-8cc8-7677953c9c7c
Written By
Mr. Sandeep Tomar (D. pharma)
Last updated
07 June 2025 | 05:03 AM (IST)